An investigation on behalf of investors of Koninklijke Philips NV (ADR) (NYSE:PHG) shares over potential securities laws violations by Koninklijke Philips NV and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Koninklijke Philips NV (ADR) (NYSE:PHG) concerning whether a series of statements by Koninklijke Philips NV regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Koninklijke Philips N.V. is a Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. Koninklijke Philips NV reported that its annual Total Revenue rose from over 24.24 billion EUR to over 24.51 billion EUR and that its Net Income increased from 400 million EUR to over 1.03 billion EUR.

On October 11, 2017, the Company announced that it reached an agreement with the U.S. Department of Justice to temporarily suspend the manufacture and distribution of certain defibrillators for the U.S. market to allow closer inspections and ensure it is in compliance with applicable U.S. Food & Drug Administration regulations.

Shares of Koninklijke Philips NV (ADR) (NYSE:PHG) closed on October 12, 2017 at $41.08 per share.